XTL Biopharmaceuticals Ltd. Provides Financial And Operational Update For The Second Quarter of 2014

HERZLIYA, Israel, Sept. 2, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. XTLB, +0.00% (tase:XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the three and six month periods ended June 30, 2014.

Josh Levine, CEO of XTL, stated: "There continues to be significant excitement about hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus, throughout the autoimmune research community.

Help employers find you! Check out all the jobs and post your resume.